Literature DB >> 10102608

Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.

R A Soslow1, H Remotti, R N Baergen, N K Altorki.   

Abstract

Esophageal adenocarcinoma often arises in association with metaplastic and dysplastic mucosa in Barrett's esophagus. Derangements in cell cycle control and apoptosis regulation might be responsible for the progression from metaplasia to dysplasia and adenocarcinoma We tested this hypothesis by performing cell cycle analysis, in situ detection of apoptosis, and evaluation for the immunohistochemical expression of proteins involved in proliferation (Ki-67), the control of apoptosis (bcl-2, bcl-x and bax), and cell cycle regulation (retinoblastoma and cyclin D1). We studied 17 randomly selected paraffin-embedded esophagectomy specimens that contained intestinal metaplasia without dysplasia, low-grade dysplasia, high-grade dysplasia, and esophageal adenocarcinoma Compared with gastric controls and intestinal metaplasia without dysplasia, high-grade dysplasia and esophageal adenocarcinoma demonstrated greater numbers of cells in S phase and G2 phase. Comparison of the proliferation index and the apoptotic rate in intestinal metaplasia without dysplasia, low-grade dysplasia, high-grade dysplasia, and esophageal adenocarcinoma showed a statistically significant trend that linked an increasing proliferation index and apoptotic rate with increasing histologic severity (P = .006 and P = .0002, respectively). A statistically significant linear association was found between bcl-x expression, bax expression, and the bcl-2-to-bax expression ratio versus increasing histologic severity (P = .0004, P = .007, and P = .03, respectively). These data support the hypothesis that neoplastic transformation of intestinal metaplastic epithelium in the esophagus might result from sequential changes in the expression of proteins involved in the control of apoptosis and the cell cycle. Furthermore, suppression of apoptosis does not seem to foster neoplastic growth in Barrett's esophagus. These observations will lead to a better understanding of the pathogenesis of esophageal adenocarcinoma and might contribute to enhancing the diagnostic accuracy when presented with dysplastic lesions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102608

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Transretinoic acid inhibits rats gastric epithelial dysplasia induced by N-methyl-N-nitro-N-nitrosoguanidine: influences on cell apoptosis and expression of its regulatory genes.

Authors:  R T Cui; G Cai; Z B Yin; Y Cheng; Q H Yang; T Tian
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

3.  Reply to letter to the editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First).

Authors:  Sri Ganeshamurthy Thrumurthy; Christopher John Lewis; Susan Pritchard; Gordon Armstrong; Stephen Edwin Arthur Attwood
Journal:  Surg Endosc       Date:  2012-01       Impact factor: 4.584

Review 4.  Role of interleukin-6 in Barrett's esophagus pathogenesis.

Authors:  Katerina Dvorak; Bohuslav Dvorak
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

Review 5.  Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction.

Authors:  Nicholas J Clemons; Wayne A Phillips; Reginald V Lord
Journal:  Cancer Biol Ther       Date:  2013-06-17       Impact factor: 4.742

6.  Sulindac prevents esophageal adenocarcinomas induced by gastroduodenal reflux in rats.

Authors:  Sung Wook Kim; Tae Jung Jang; Ki Hoon Jung; Jung Il Suh
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.